Compare Quest Diagnostics Inc (DGX) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Phillips 66 — how do they compare? Quest Diagnostics Inc trades at $237.94 (market cap $26.21B), while Phillips 66 trades at $225.82 (market cap $89.52B). The key difference: Phillips 66 is far larger — about 3.4× Quest Diagnostics Inc's market cap, and Phillips 66 pays the higher dividend (2.26%). Which is the better fit depends on your goals.
| DGX | PSX | |
|---|---|---|
Market Cap | $26.21B | $89.52B |
Sector | Health | Energy |
52-Week High | $238.50 | $224.36 |
52-Week Low | $173.49 | $120.04 |
Enterprise Value | $31.97B | $105.99B |
Dividend Yield | 1.45% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Phillips 66 (PSX) trades at $225.48, up 4.62% today, with a bullish technical signal supported by moving averages and strong earnings beats. Recent Q2 2026 EPS of $9.41 exceeded expectations, driven by robust refining margins. The company announced a $5 billion joint venture for the Western Gateway Pipeline, signaling growth in midstream operations. Valuation metrics appear attractive with a P/E of 12.81 and P/S of 0.6, while profitability remains solid with a 24.02% ROE.
Outlook is positive due to sustained refining tightness and debt reduction, but risks include volatile crude prices and regulatory pressures. Analysts are bullish with a $221.92 consensus target, though the stock faces near-term resistance at $227. Revenue is projected to rebound to $152.2B in 2026, supporting a hold or buy stance for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
